eCysticFibrosis Review

Take our post-test to claim CME credits. No-contact telemedicine to better protect CF clinic patients and staff during this pandemicmay sound like a great idea, but is it even possible to institute? In thiseCysticFibrosisReviewSpecial Edition podcast, we find out how pulmonary andcriticalcarespecialistsDr.DanaAlbonand Dr.Lindsay Somervillesuccessfully brought telemedicine to theirAdult Cystic Fibrosis Clinic at University of Virginia Health. The post Bringing Telemedicine to the CF Clinic: A Success Story appeared first on DKBmed Radio.

Take our post-test to claim CME credits. To read a companion newsletterclick here. Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What’s known about CFTR modulator effects on cystic fibrosis-associated liver disease? In thiseCysticFibrosisReview podcast, Drs.Darla ShoresandAnna Reedfrom theTHRIVE Pediatric Intestinal Rehabilitation Centerin the Division of Gastroenterology,Hepatology, and Nutrition at the Johns Hopkins Children's Centertake us to the clinic to answer these and other questions crucial to the health of our patients with cystic fibrosis. The post CFTR, Growth & Liver Disease: A Clinical Perspective appeared first on DKBmed Radio.

Take our post-test to claim CME credits. To read a companion newsletterclick here. Elexacaftor/tezacaftor/ivacaftor—thenewly approvedtriple combinationCFTRmodulatortherapy.What are the benefits?For which patients?What are the potential adverse effects?Who’s most likely to receive them? In this issue,Dr. ScottSagelfrom the Breathing Instituteat the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus,takes us to the clinic to discusssome answers. The post In the Clinic: Triple Combination CFTR Modulation appeared first on DKBmed Radio.

Take our post-test to claim CME credits. To read a companion newsletterclick here. Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work? In this issue, Dr. Anna Georgiopoulos,Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psychiatrist, Massachusetts General Hospital Cystic Fibrosis Program,takes us to the clinic to answer these questions that can be key to the health and well-being of children, adults, and families living with CF. The post Addressing Mental Health in CF appeared first on DKBmed Radio.

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies. Take our post-test to claim CME credits. To read a companion newsletterclick here. The post Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators appeared first on DKBmed Radio.

Volume 8, Issue 11. In this issue: Inhaled antibiotics have become the foundation of treating chronic respiratory tractPseudomonasinfection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents? Which medications are appropriate for continuous alternating therapy (CAT)? In this Issue, Dr. Elliott Dasenbrook from theCleveland Clinic brings the evidence he analyzed in his recenteCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making. Take our post-test to claim CME credits. To read a companion newsletterclick here. The post Continuous Alternating Therapies: A Clinical Perspective appeared first on DKBmed Radio.